Donor-specific antibodies require preactivated immune system to harm renal transplant

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F16%3A00060021" target="_blank" >RIV/00023001:_____/16:00060021 - isvavai.cz</a>

Výsledek na webu

<a href="http://ac.els-cdn.com/S235239641630250X/1-s2.0-S235239641630250X-main.pdf?_tid=6074f266-99eb-11e6-a3c7-00000aab0f02&acdnat=1477314869_05d8195977e03b5e82b940d2856d6015" target="_blank" >http://ac.els-cdn.com/S235239641630250X/1-s2.0-S235239641630250X-main.pdf?_tid=6074f266-99eb-11e6-a3c7-00000aab0f02&acdnat=1477314869_05d8195977e03b5e82b940d2856d6015</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.ebiom.2016.06.006" target="_blank" >10.1016/j.ebiom.2016.06.006</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Donor-specific antibodies require preactivated immune system to harm renal transplant

Popis výsledku v původním jazyce

Background: It is an unresolved issue why some kidney transplant recipients with pretransplant donor-specific HLA antibodies (DSA) show a high transplant failure rate, whereas in other patients DSA do not harm the graft. We investigated whether help from preactivated T-cells might be necessary for DSA to exert a deleterious effect. Methods: The impact of pretransplant DSA and immune activation marker soluble CD30 (sCD30) on 3-year graft survival was analyzed in 385 presensitized kidney transplant recipients. Findings: A deleterious influence of pretransplant DSA on graft survival was evident only in patients who were positive for the immune activation marker sCD30. In the absence of sCD30 positivity, 3-year graft survival was virtually identical in patients with or without DSA (83.1 +/- 3.9% and 84.3 +/- 2.8%, P = 0.81). A strikingly lower 3-year graft survival rate of 62.1 +/- 6.4% was observed in patients who were both sCD30 and DSA positive (HR 2.92, P < 0.001). Even in the presence of strong DSA with }= 5000 MFI, the 3-year graft survival rate was high if the recipients were sCD30 negative. Interpretation: Pretransplant DSA have a significantly deleterious impact on graft survival only in the presence of high pretransplant levels of the activation marker sCD30. (C) 2016 The Authors. Published by Elsevier B.V.

Název v anglickém jazyce

Donor-specific antibodies require preactivated immune system to harm renal transplant

Popis výsledku anglicky

Background: It is an unresolved issue why some kidney transplant recipients with pretransplant donor-specific HLA antibodies (DSA) show a high transplant failure rate, whereas in other patients DSA do not harm the graft. We investigated whether help from preactivated T-cells might be necessary for DSA to exert a deleterious effect. Methods: The impact of pretransplant DSA and immune activation marker soluble CD30 (sCD30) on 3-year graft survival was analyzed in 385 presensitized kidney transplant recipients. Findings: A deleterious influence of pretransplant DSA on graft survival was evident only in patients who were positive for the immune activation marker sCD30. In the absence of sCD30 positivity, 3-year graft survival was virtually identical in patients with or without DSA (83.1 +/- 3.9% and 84.3 +/- 2.8%, P = 0.81). A strikingly lower 3-year graft survival rate of 62.1 +/- 6.4% was observed in patients who were both sCD30 and DSA positive (HR 2.92, P < 0.001). Even in the presence of strong DSA with }= 5000 MFI, the 3-year graft survival rate was high if the recipients were sCD30 negative. Interpretation: Pretransplant DSA have a significantly deleterious impact on graft survival only in the presence of high pretransplant levels of the activation marker sCD30. (C) 2016 The Authors. Published by Elsevier B.V.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

EC - Imunologie

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

EBioMedicine [online]

ISSN

2352-3964

e-ISSN

—

Svazek periodika

9

Číslo periodika v rámci svazku

July 2016

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

6

Strana od-do

366-371

Kód UT WoS článku

000381622500046

EID výsledku v databázi Scopus

—